Sequencing systemic therapies in advanced RCC: is there a best strategy?
Am Soc Clin Oncol Educ Book
; 2013.
Article
in En
| MEDLINE
| ID: mdl-23714492
ABSTRACT
There is a strong rationale for sequencing targeted therapy in metastatic clear cell renal cancer. However the timing of the switch and the best agent to switch to remains unclear. Randomized data currently are supportive of the sequence of axitinib, followed by everolimus in those patients in which first-line vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) therapy fails. Everolimus is also justified in the second-line setting, and the overall survival data for sorafenib in VEGF TKI resistant disease is impressive. A degree of cross-resistance appears to exist between all these current agents and has resulted in a drive toward the development of new therapies with novel modes of action.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Antineoplastic Combined Chemotherapy Protocols
/
Kidney Neoplasms
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Am Soc Clin Oncol Educ Book
Year:
2013
Document type:
Article
Affiliation country:
United kingdom